Vontobel Holding Ltd. Raises Stake in BioNTech SE (NASDAQ:BNTX)

Vontobel Holding Ltd. increased its holdings in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 24.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,385 shares of the company's stock after purchasing an additional 4,227 shares during the period. Vontobel Holding Ltd.'s holdings in BioNTech were worth $2,437,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Baillie Gifford & Co. grew its position in BioNTech by 0.4% during the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company's stock worth $986,750,000 after purchasing an additional 31,773 shares during the last quarter. FMR LLC grew its position in BioNTech by 797.8% during the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company's stock worth $748,243,000 after purchasing an additional 5,598,190 shares during the last quarter. Fred Alger Management LLC purchased a new position in BioNTech during the 3rd quarter worth $59,485,000. DekaBank Deutsche Girozentrale grew its position in BioNTech by 12.6% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 481,397 shares of the company's stock worth $56,886,000 after purchasing an additional 53,800 shares during the last quarter. Finally, abrdn plc grew its position in BioNTech by 70.7% during the 4th quarter. abrdn plc now owns 385,668 shares of the company's stock worth $43,947,000 after purchasing an additional 159,676 shares during the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Price Performance

Shares of NASDAQ BNTX traded down $1.70 during midday trading on Thursday, hitting $117.88. The company had a trading volume of 866,053 shares, compared to its average volume of 728,025. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $131.49. The business has a 50-day simple moving average of $117.33 and a two-hundred day simple moving average of $110.25. The firm has a market capitalization of $28.26 billion, a price-to-earnings ratio of -56.13 and a beta of 0.17.

Analysts Set New Price Targets

BNTX has been the topic of several research reports. Truist Financial initiated coverage on shares of BioNTech in a research report on Friday, January 10th. They set a "buy" rating and a $172.00 price objective on the stock. BMO Capital Markets restated an "outperform" rating on shares of BioNTech in a research note on Monday, December 2nd. JPMorgan Chase & Co. reduced their target price on shares of BioNTech from $124.00 to $122.00 and set a "neutral" rating for the company in a research note on Tuesday, November 26th. TD Cowen reduced their target price on shares of BioNTech from $132.00 to $122.00 and set a "hold" rating for the company in a research note on Tuesday, November 5th. Finally, Berenberg Bank assumed coverage on shares of BioNTech in a research note on Tuesday, November 19th. They issued a "buy" rating and a $130.00 target price for the company. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $142.72.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.